A recent study concludes that Opana is a new reliable treatment option for pain management in those who suffer from neuropathic cancer pain. Ten of the 27 patients in the study who had neuropathic cancer-related pain completed the study. The others who entered the study but did not complete it left the study for a variety of reasons, such as loss of effectiveness, nonadherence and adverse reactions, although none of them included serious risk to the patient. Less than half of the patients in the study reported adverse affects, and those who did reported minor ones such as fatigue, dry mouth and constipation.
Source
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment